Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 102 64 | DOI: 10.1530/endoabs.102.64

1Endocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine; 2Medical Laboratory CSD, Kyiv, Ukraine; 3Laboratory of Epigenetics, Institute of Gerontology Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 4Taras Shevchenko National University of Kyiv, Kyiv, Ukraine


Background and aims: Leukocyte telomere length (LTL) is considered as a promising prognostic marker associated with COVID-19 severity, adverse outcomes (hospital admission, need for critical care, respiratory support), and mortality. However, LTL contribution to long COVID development is unclear. In this study, we aimed to evaluate the relationship between LTL and long COVID development in type 2 diabetes patients (T2D) concerning clinical phenotype, gender, and biological age.

Material and Methods: In this cross-sectional study, 68 T2D patients were enrolled. Inclusion criteria: age over 18 years, presence of T2D and COVID-19 infection confirmed by positive RT-PCR test. Patients were divided into 2 groups depending on long COVID presence: long COVID group (n = 46) and patients who didn’t develop post COVID syndrome (comparison group, n = 22) for up to 6 months after COVID-19 infection. A standardized method of quantitative monochrome multiplex polymerase chain reaction in real-time was used to determine the relative LTL.

Results: Our research showed significantly lower LTL in T2D patients with long COVID compared to the comparison group (1.1±0.2 vs 1.28±0.24; P = 0.003). LTL negatively correlated with IL-6 (r = -0.318; P = 0.035) and hs-CRP levels (r = -0.322; P = 0.033) in the long COVID group, reflecting the role of inflammation in accelerating senescence though there was no statistically significant difference in IL-6 and hs-CR. In sub-analysis shorter LTL was observed in females and patients older in both groups. Shorter LTL was an independent predictor associated with the development of long COVID in patients with T2D (OR 0.026; 95%CI 0.002-0.354; P = 0.006). LTL with a cut-off value ≤1.02 can be considered as prognostic biomarker of long COVID development (sensitivity 39.1%, specificity 95.5%). The AUROC for the model was 0.691 95% CI 0.561-0.820 (P = 0.004).

Conclusions: The results of this study demonstrated that long COVID is associated with an accelerated aging pattern of LTL that could impact the future course of T2D and patients outcomes.

Volume 102

ESE Young Endocrinologists and Scientists (EYES) 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.